Akeso and Summit unveil survival data showing their bispecific antibody outperforms Merck's Keytruda
Akeso and Summit Therapeutics have released detailed survival results from a trial comparing their PD-1xVEGF bispecific antibody to Keytruda, following an earlier announcement of a significant win. The data, presented in early September, are expected to strengthen the case for the drug as a potential first-line treatment in certain cancers. The companies hope the full results will support regulatory submissions and broader clinical adoption.
The detailed survival figures from the comparative trial were presented in early September, following an earlier announcement that the bispecific antibody had achieved a significant advantage over Merck's established immunotherapy. The data specifically position the PD-1xVEGF bispecific antibody as a potential first-line option for certain cancer types.
Akeso and Summit intend to use these full results to support regulatory submissions and encourage broader clinical adoption. The outcome suggests a shift in the competitive landscape for cancer immunotherapies, with bispecific approaches potentially offering an alternative to existing PD-1 inhibitors.
The results could reshape treatment options for patients with certain cancers, potentially offering a more effective first-line therapy than the current standard. If regulatory submissions succeed, this may expand access to bispecific antibodies and influence how oncologists sequence treatments. However, broader adoption will depend on confirmatory data, safety profiles, and cost considerations. Patients and clinicians could benefit from additional choices, while the competitive pressure may prompt further innovation in immunotherapy research.